Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.